文献速递心律失常

CASQ2-儿茶酚胺敏感性多形性室速的遗传模式、心律失常风险与机制:国际多中心评估

An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia.
PubMed 文献 · Circulation · 2020-07-22

该国际多中心研究评估了CASQ2-CPVT的遗传模式与心律失常风险,发现CASQ2纯合/复合杂合子临床外显率97.1%,且76.5%发生潜在致死性心律失常事件(中位年龄7岁);33.3%的杂合家庭成员符合CPVT诊断标准。研究提示致病性杂合CASQ2变异可表现为CPVT表型,需临床筛查,某些错义变异因位置和功能呈现显性遗传模式。

要点

  • CASQ2纯合/复合杂合子临床外显率97.1%,76.5%发生潜在致死性心律失常事件,中位年龄7岁。
  • 33.3%的CASQ2杂合家庭成员符合CPVT诊断标准,提示杂合子需临床筛查。
  • 某些错义变异因位于CASQ2丝状结构关键区域而呈现显性遗传模式。

核心结论

  • CASQ2-CPVT的遗传模式需重新定义,致病性杂合CASQ2变异可表现为CPVT表型,某些错义变异因位置和功能呈现显性遗传模式。

研究设计与样本

  • 国际多中心研究,纳入112例个体,包括36例CPVT先证者(24例纯合/复合杂合,12例杂合)和76名携带至少1个推测致病CASQ2变异的家庭成员。
  • 评估CASQ2-CPVT家系的基因型-表型分离,采用Cox回归模型评估基因型对心律失常风险的影响。
  • 对候选显性CASQ2错义变异和已知隐性CASQ2-p.R33Q变异进行寡聚化测定,并定位至近期CASQ2丝状结构。

主要发现

  • CASQ2纯合/复合杂合子临床外显率97.1%,34例中26例(76.5%)经历潜在致死性心律失常事件,中位发病年龄7岁(95%CI,6-11)。
  • 66名CASQ2杂合家庭成员中51名接受临床评估,17名(33.3%)符合CPVT诊断标准。
  • 先证者中纯合/复合杂合基因型相比杂合子,心脏晕厥、流产性心脏骤停和心源性猝死复合终点风险增加3.2倍(95%CI,1.3-8.0;P=0.013);基因阳性家庭成员中风险增加38.8倍(95%CI,5.6-269.1;P<0.001)。
  • 体外浊度测定显示p.R33Q和所有6个候选显性CASQ2错义变异均存在丝状化缺陷,但仅p.R33Q明确未能二聚化。
  • 结构分析显示6个推测显性负性错义变异中3个定位于被认为对二聚体背靠背结合关键的负电口袋。

临床怎么用

  • 对致病性杂合CASQ2变异携带者应进行临床筛查,因其可能表现为CPVT表型。
  • CASQ2纯合/复合杂合子患者心律失常事件风险高且发病年龄早,需密切监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic variants in calsequestrin-2 (CASQ2) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2-CPVT was sought through an international multicenter collaboration. METHODS: Genotype-phenotype segregation in CASQ2-CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. RESULTS: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6-11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3-8.0; P=0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6-269.1; P<0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. CONCLUSIONS: This international multicenter study of CASQ2-CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ng K, Titus EW, Lieve KV, et al. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2020. PMID: 32693635. doi:10.1161/CIRCULATIONAHA.120.045723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。